| DC 欄位 |
值 |
語言 |
| DC.contributor | 企業管理學系 | zh_TW |
| DC.creator | 楊英煥 | zh_TW |
| DC.creator | Ying-huan Yang | en_US |
| dc.date.accessioned | 2013-6-25T07:39:07Z | |
| dc.date.available | 2013-6-25T07:39:07Z | |
| dc.date.issued | 2013 | |
| dc.identifier.uri | http://ir.lib.ncu.edu.tw:88/thesis/view_etd.asp?URN=100421034 | |
| dc.contributor.department | 企業管理學系 | zh_TW |
| DC.description | 國立中央大學 | zh_TW |
| DC.description | National Central University | en_US |
| dc.description.abstract | 生技產業為技術密集且具高度創新性之高附加價值產業，主要以醫藥品最受矚目。因為生技產品受法規管制，導致產品開發期長、投資風險高而使資金募集不易，許多企業難以支撐到產品上市階段，因此企業提升研發效率，是生技醫藥產業發展重要的基礎。反觀美國生物科技之所以能成為產業龍頭，因為有源源不斷的創新技術從學術研究機構擴散至產業界，科學家與產業的互動形成社會與科技所交織的網絡關係，因此本研究應用行動者網絡理論的概念，針對行動者利害關係、知識轉譯、情境轉換而形成異質化網絡進行探討，了解生技廠商如何透過網絡合作以提升研發績效。
雖然過去學者已利用多階段資料包絡分析，透過變數進行企業研發效率之評估，但卻忽略了將網絡概念納入企業績效評估的研究中。因此本研究將行動者網絡理論在生技產業的情境轉換建立企業研發績效模型，並採用網絡資料包絡分析法針對技術創造能力、技術擴散能力和價值創造能力進行效率評估。本研究對象為國內22家生技醫藥廠商。研究結果發現台灣醫藥廠商總體研發效率有待提升，技術創造能力顯示出國內專利不足，標竿分群指出技術合作群研發效率高於獨立發展群，表示網絡合作能提高研發效率。本研究建議生技產業透過產學官異質化網絡的合作及產業群落的形成，將可創造行動者網絡中強制通行點，研發產業鏈的專業化分工，不但可降低營運及研發上的風險，並有助於提升產業規模與研發績效。 | zh_TW |
| dc.description.abstract | Biotechnology industry is technology-intensive, highly innovative and high value-added industries. Especially in the pharmaceutical industry. Because biotech products subject to regulatory control. Resulting in long product development, funds raised is not easy because high investment risk. Difficult for many businesses to support to the stage to market, so efficient R&D performance is important foundation of the development of the biotechnology pharmaceutical industry. The other hand, the U.S. biotech industry become the industry leader because a steady stream of innovative technologies from academic and research institutions spread to the industry. The formation of social and technological interwoven network relationships in Scientists and industry. Therefore, this study applied the concept of Actor-Network Theory(ANT), the formation of a heterogeneous network in actor interessment, knowledge translation, situational conversion. Explore how to improve the biotechnology industries’ R&D performance by network cooperation.
Although researchers have used multi-stage DEA and variables to measure R&D performance in the past, but they ignores the network concept into R&D performance evaluation studies. Therefore, this study establishes R&D performance model by situational conversion of biotechnology industry in Actor-Network Theory and network DEA -technology creation capability, technology diffusion capability and value creation capability, and analyze R&D performance of 22 biotechnology pharmaceutical corporations in Taiwan. The study finds the overall Taiwanese pharmaceutical industries’ R&D performance should be improved. Technology creation capability shows insufficient domestic patent. The technical cooperation group is more efficient than independent development in benchmarking. It shows R&D performance can be improved by Network cooperation. This study suggests that biotechnology industries create obligatory passage point(OPP) in ANT by industry-academic-government heterogeneous network collaboration and industry clusters. specialization and division of labor establish value chain can not only reduce the risk of operation and R&D but also step up industry scale and R&D performance. | en_US |
| DC.subject | 行動者網絡理論 | zh_TW |
| DC.subject | 生技醫藥產業 | zh_TW |
| DC.subject | 資料包絡分析 | zh_TW |
| DC.subject | 研發績效評估 | zh_TW |
| DC.subject | Actor Network theory | en_US |
| DC.subject | Patent indicators | en_US |
| DC.subject | Data envelopment analysis | en_US |
| DC.subject | R& | en_US |
| DC.subject | D performance Measurement | en_US |
| DC.title | 應用行動者網絡理論探討企業研發績效 －以生技醫藥產業為例 | zh_TW |
| dc.language.iso | zh-TW | zh-TW |
| DC.title | Use Actor-Network Theory for R&D Performance The Case of Biotechnology Pharmaceutical Industry | en_US |
| DC.type | 博碩士論文 | zh_TW |
| DC.type | thesis | en_US |
| DC.publisher | National Central University | en_US |